Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Miconazole NitratePolymyxin B SulfatePrednisoline Acetate

Administration Routes

Auricular (Otic)OphthalmicUnknown

Species Affected

Dog 12
Human 1

Most Affected Breeds

Crossbred Canine/dog 3
Terrier - Yorkshire 2
Unknown 1
Shepherd Dog - German 1
Bichon Frise 1
Pekingese 1
Poodle - Miniature 1
Pinscher - Miniature 1
Lhasa Apso 1
Terrier - Irish Soft-coated Wheaten 1

Most Reported Reactions

Deafness 6
Blindness 2
Loss of hearing 2
Eye pain 1
Double vision 1
Accidental exposure 1
Uveitis 1
Cataract 1
Retinal detachment 1
Impaired hearing 1
Hearing decreased 1
Blue eye 1

Outcome Breakdown

Recovered/Normal
5 (38.5%)
Outcome Unknown
3 (23.1%)
Recovered with Sequela
3 (23.1%)
Ongoing
2 (15.4%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 10
Distinct reactions reported 16
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Miconazole Nitrate, Polymyxin B Sulfate, Prednisoline Acetate. Reported administration routes include Auricular (Otic), Ophthalmic, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate reports are Dog (12 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (3), Terrier - Yorkshire (2), Unknown (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate are Deafness (6), Blindness (2), Loss of hearing (2), Eye pain (1). Of the 13 reports with a coded outcome, Recovered/Normal is the leading category at 38.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Miconazole Nitrate + Polymyxin B Sulfate + Prednisoline Acetate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial